

Cancer Molecular Therapeutics Research Association (CMTRA) Annual Conference 2025 Schedule and Program July 13-17, 2025

Sunday, July 13: Homestead Resort, Garden Room

*All events will be held in the Garden Room or Garden Room Patio, unless otherwise specified

4:00-6:00 pm	Arrival & Check-In
6:00-7:00 pm	Dinner
7:30-7:45 pm	<p>WELCOME AND INTRODUCTION: Martin McMahon, PhD President, CMTRA Sr. Director of Preclinical Translation, Huntsman Cancer Institute Professor, Dept. of Dermatology, University of Utah</p>
7:45-8:45 pm	<p>KEYNOTE SPEAKER: Ralph DeBerardinis, MD, PhD Chief of Pediatric Genetics & Metabolism, UT Southwestern <i>“Metabolic profiling in patients – lessons in disease mechanism and therapy”</i></p>
9:00 pm	Welcome Reception

Monday, July 14, 2025: Morning

7:30-8:15 am	Breakfast
8:30 am-12:00 pm	<p>MORNING SESSION: Next Generation Antibody-Drug Conjugates Discussion Leader: Shiva Malek, PhD, Board Member, CMTRA EVP, Global Head, Oncology Disease Area, Novartis</p>
8:30-8:45 am	Introduction: Shiva Malek, PhD

8:45-9:15 am	<p>Puja Sapra, PhD Senior VP, Biologics Engineering & Oncology Targeted Discovery, AstraZeneca <i>“Antibody Drug Conjugates redefining cancer therapy: lessons learned & future possibilities”</i></p>
9:15-9:45 am	Discussion
9:45-10:05 am	Coffee Break
10:05-10:35 am	<p>Sarat Chandarlapaty, MD, PhD Professor of Medicine, Memorial Sloan Kettering Cancer Center <i>“Determinants of HER2 ADC Response and Resistance”</i></p>
10:35-11:05 am	Discussion
11:05-11:25 am	<p>Hans-Peter Gerber, PhD Chief Scientific Officer, Sutro Biosciences <i>“Enhancing ADCs Both Within and Outside the Tumor Leads to a Higher Therapeutic Index”</i></p>
11:25-11:45 am	Discussion
12:00-1:00 pm	Lunch
1:00-5:00 pm	<p>OPEN NETWORKING AFTERNOON Activities at the Homestead: swimming in pools and the crater, golf, and ATV rides. See the hotel for more info.</p>
5:00-6:30 pm	Poster Session and Social
6:30-7:30 pm	Dinner
Monday, July 14, 2025: Evening	
7:30-9:45 pm	<p>EVENING SESSION: Exposure-induced Cancers Discussion Leader: Michelle Arkin, PhD Board Member, CMTRA Professor, Pharmaceutical Chemistry, UCSF</p>
7:30-7:45 pm	Introduction: Michelle Arkin, PhD
7:45-8:15 pm	<p>Aria Vaishnavi, PhD Asst. Professor, Dept. of Cancer Biology, MD Anderson Cancer Center</p>

	<i>“Unraveling the Molecular Mechanisms of Radon and Air Pollution-induced Lung Cancers”</i>
8:15-8:45 pm	Discussion
8:45-9:15 pm	Jean Nakamura, MD Professor, Radiation Oncology, UCSF <i>“Ionizing Radiation-Induced Malignancies: Background Matters”</i>
9:15-9:45 pm	Discussion
9:45 pm	Social, Hospitality Suite
Tuesday, July 15, 2025: Morning	
7:30-8:15 am	Breakfast
8:30 am-Noon	MORNING SESSION: Extrachromosomal DNA Discussion Leader: Bob Abraham, PhD Board Member, CMTRA CSO, Engine Biosciences Scientific advisor, GV
8:30-8:45 am	Introduction: Bob Abraham, PhD
8:45-9:15 am	Paul Mischel, MD Professor and Vice Chair for Research, Dept. of Pathology, Stanford Medicine <i>“Extrachromosomal DNA (ecDNA): Cancer’s Dynamic Circular Genome”</i>
9:15-9:40 am	Discussion
9:40-10:00 am	<i>Group Photograph on Garden Patio</i> Coffee Break
10:00–10:30 am	Chris Hassig, PhD Chief Scientific Officer, Boundless Bio <i>“Synthetic Lethality in a Plastic Genome, Intercepting ecDNA Biology”</i>
10:30-11:00 am	Discussion
11:00-11:30 am	Andrea Ventura, MD, PhD Member, Memorial Sloan Kettering Cancer Center

	<i>“ecDNA-Driven Oncogenesis: From in vitro Engineering to Mouse Models”</i>
11:30-12 Noon	Discussion
12:00-1:00 pm	Lunch
1:00-5:00 pm	OPEN NETWORKING AFTERNOON
5:00-6:30 pm	<p>PANEL DISCUSSION: “Navigating the Venture Capital-Biotech Ecosystem” Discussion Leader: Bob Abraham, PhD Engine Biosciences</p> <p>Panelists:</p> <ul style="list-style-type: none"> ● Karthik Ardhanareeswaran, GV ● Alexandra Cantley, PhD, Polaris Partners ● Julie Grant, PhD, Canaan ● Frank McCormick, PhD, UCSF
6:30-7:30 pm	Dinner
Tuesday, July 15, 2025: Evening	
7:30-9:45 pm	<p>EVENING SESSION: Progress targeting the YAP/TAZ/TEAD pathway Discussion Leader: Eli Wallace, PhD CEO, BBOT</p>
7:30-7:45 pm	Introduction: Eli Wallace, PhD
7:45-8:15 pm	<p>Laurent Sansregret, PhD Sr. Principal Scientist, Novartis <i>“Pharmacological targeting of YAP/TEAD-driven cancer dependency”</i></p>
8:15-8:40 pm	Discussion
8:45-9:15 pm	<p>Anwasha Dey, PhD Distinguished Scientist and Exec. Director, Genentech <i>“Targeting the Hippo Pathway in Cancers”</i></p>
9:15-9:40 pm	Discussion
9:40 pm	Social, Hospitality Suite
Wednesday, July 16, 2025: Morning	

7:30-8:15 am	Breakfast
8:30 am-12:00 pm	MORNING SESSION: Breakthroughs in Cancer Epigenetics Discussion Leader: Lori Friedman, PhD CSO, ORIC Pharmaceuticals
8:30-8:45 am	Introduction: Lori Friedman, PhD
8:45-9:15 am	Kunal Rai, PhD Assoc. Professor of Genomic Medicine, MD Anderson Cancer Center <i>“Epigenome Reprogramming During Response to Immunotherapy”</i>
9:15-9:40 am	Discussion
9:40-10:00 am	Coffee Break
10:00-10:30 am	Karim-Jean Armache, PhD Professor of Biochemistry, NYU <i>“Molecular Mechanisms of Chromatin Modifying Enzymes”</i>
10:30-10:55 am	Discussion
11:00-11:30 am	Arul Chinnaiyan, MD, PhD Professor of Pathology and Urology, Univ. of Michigan <i>“Targeting p300/CBP in oncogenic transcription factor-driven cancers”</i>
11:30-11:55 am	Discussion
12:00-1:00 pm	Lunch
1:00 - 2:00 pm	Break
2:00-5:00 pm	AFTERNOON SESSION: Targeting RAS Oncoproteins; Lessons from the Lab and the Clinic Discussion Leader: Martin McMahon, PhD Professor, University of Utah, Huntsman Cancer Institute
2:00-2:15 pm	Introduction: Martin McMahon, PhD
2:15-2:45 pm	Frank McCormick, PhD, FRS Professor, UCSF Cancer Center

	<i>“New Opportunities for Targeting RAS and Its Effectors”</i>
2:45-3:05 pm	Discussion
3:05–3:35 pm	Matthew Holderfield, PhD Exec. Director, Revolution Medicines <i>“RAS(ON) Inhibitors Reveal Mechanisms of RAS Oncogene Addiction”</i>
3:35-4:05 pm	Discussion
4:05-4:35 pm	Ferdinandos Skoulidis, MD, PhD Assist. Professor, MD Anderson Cancer Center <i>“Decoding Response and Tolerance to RAS inhibitors in NSCLC”</i>
4:35-5:00 pm	Discussion
5:00-6:00 pm	Break
6:00-7:00 pm	Dinner
Wednesday, July 16, 2025: Evening	
7:15-8:15 pm	KEYNOTE SPEAKER: Karen Cichowski, PhD Professor, Harvard Medical School <i>“Developing Combinatorial Therapies for RAS Pathway-driven Cancers”</i>
8:30-10:00 pm	Closing Reception
Thursday, July 17, 2025	
Breakfast on your own. Onsite options: The Milk House, open 7 am, Simon’s Restaurant, open 8 am	
11:00 am	Check out by 11:00 am

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photography or recording of sessions, posters, or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

THIS MEETING WOULD NOT BE POSSIBLE WITHOUT GENEROUS CONTRIBUTIONS FROM OUR MANY FRIENDS AND COLLEAGUES, INCLUDING: BRISTOL-MEYERS SQUIBB, LILLY, GENENTECH, HUNTSMAN CANCER INSTITUTE, REV MED, AND PFIZER.

MANY THANKS TO EACH OF YOU WHO CONTRIBUTED.

ANNUAL CONFERENCE 2025



CMTRA

**The Cancer Molecular Therapeutics
Research Association**

CMTRA 2025 DELEGATES

Last	First	Affiliation	Email
Hadzipasic	Addy	Novartis	addy.hadzipasic@novartis.com
Dorrance	Adrienne	Huntsman Cancer Institute	adrienne.dorrance@gmail.com
Cantley	Alexandra	Polaris Partners	acantley@polarispartners.com
Ventura	Andrea	MSKCC	venturaa@mskcc.org
Dey	Anwasha	Genentech	dey.anwasha@gene.com
Vaishnavi	Aria	MD Anderson	avaishnavi1@mdanderson.org
Chinnaiyan	Arul	U Michigan	arul@med.umich.edu
Toshniwal	Ashish	Huntsman Cancer Institute	ashishgtoshniwal@gmail.com
Venkatanarayan	Avinash	Merck	avinashnarayan.venkatanarayan@merck.com
Zaro	Balyn	UCSF	balyn.zaro@ucsf.edu
Spike	Ben	Huntsman Cancer Institute	benjamin.spike@hci.utah.edu
Li	Bingbing	Oregon Health Sciences Univ.	lib@ohsu.edu
Abraham	Bob	Odyssey Therapeutics	abrahamrobert20@gmail.com
Murphy	Brandon	Huntsman Cancer Institute	brandon.murphy@hci.utah.edu
Keller	Charles	Children's Cancer Therapy Development Inst.	charles@cc-tdi.org
Tsao	Cheng-Chung	Lilly	tsao_cheng_chung@lilly.com
Hassig	Chris	Boundless Bio	chassig@boundlessbio.com
Kinsey	Conan	Huntsman Cancer Institute	conan.kinsey@hsc.utah.edu
Reshef	David	GV	dr@gv.com
Wallis	Deeann	Univ. of Alabama at Birmingham	dwallis@uab.edu
Nissley	Dwight	NIH	nissleyd@mail.nih.gov
Wallace	Eli	BridgeBio Pharma	eli.wallace@bridgebiooncology.com
Lees	Emma	Bristol Myers Squibb	emma.lees@bms.com
Newcomb	Eric	Newcomb Medicinal Chemistry	eric@newcombmedchem.com
Skoulidis	Ferdinandos	MD Anderson	fskoulidis@mdanderson.org
McCormick	Frank	UCSF	frank.mccormick@ucsf.edu

Szulzewsky	Frank	Huntsman Cancer Institute	Frank.Szulzewsky@hsc.utah.edu
Neuendorf	Hannah	Huntsman Cancer Institute	hannah.neuendorf@hci.utah.edu
Bitter	Hans	Takeda	hans.bitter@takeda.com
Gerber	Hanspeter	Sutro Biopharma	hgerber@sutrobio.com
Essel Dadzie	Headtlove	Huntsman Cancer Institute	u1317053@utah.edu
Frosch	Hyejin	Bristol Myers Squibb	hcho1303@gmail.com
Nakamura	Jean	UCSF	jean.nakamura@ucsf.edu
Grant	Julie	Canaan Partners	jgrant@canaan.com
Heslop	Kareem	Genentech	heslopk@gene.com
Cichowski	Karen	Harvard Division of Medical Sciences	kcichowski@rics.bwh.harvard.edu
Armache	Karim-Jean	NYU Langone Health	karim-jean.armache@nyulangone.org
Ardhanareeswaran	Karthik	GV	kxa@gv.com
O'Toole	Kayla	Huntsman Cancer Institute	Kayla.OToole@hci.utah.edu
Rai	Kunal	MD Anderson	krai@mdanderson.org
Sansregret	Laurent	Novartis	laurent.sansregret@novartis.com
Friedman	Lori	ORIC Pharmaceuticals	lori.friedman@oricpharma.com
McBride	Mandi	Huntsman Cancer Institute	mandi.mcbride@hci.utah.edu
McMahon	Martin	Huntsman Cancer Institute	martin.mcmahon@hci.utah.edu
Timson	Mary	Deciphera	mtimson@deciphera.com
Holderfield	Matt	RevMed	mholderfield@revmed.com
Patricelli	Matthew	Vividion	mattp@vividion.com
Arkin	Michelle	UCSF	michelle.arkin@ucsf.edu
Piper	Miles	Huntsman Cancer Institute	miles.piper@hci.utah.edu
Foth	Mona	Huntsman Cancer Institute	mona.foth@hci.utah.edu
Gitego	Nadege	BridgeBio Pharma	nadege.gitego@bridgebiooncology.com
Emmanuel	Natasha	Tesseract Med	natasha.emmanuel@tesseractmed.com
Mischel	Paul	Stanford	pmischel@stanford.edu
Sapra	Puja	Astra Zeneca	Puja.Sapra@astrazeneca.com

DeBerardinis	Ralph	UT Southwestern	ralph.deberardinis@utsouthwestern.edu
Judson-Torres	Robert	Huntsman Cancer Institute	Robert.Judson-Torres@hci.utah.edu
Kramer	Robert	Portage Biotech	robert.kramer33@verizon.net
Francois	Rony	UCSF	rony.francois@ucsf.edu
Chandarlapaty	Sarat	MSKCC	chandars@mskcc.org
Bali	Semiha Kevser	Lawrence Livermore National Laboratory	bali2@llnl.gov
Malek	Shiva	Novartis	shiva.malek@novartis.com
Hwang	Stuart	Remiges Ventures	stuart.hwang@gmail.com
El Mellouki	Tarik	Deciphera	tarik.elmellouki@deciphera.com
Schoenbeck	Uwe	Canaan Partners	uschoenbeck@canaan.com
Khan	Zaigham	St. Jude	Zaigham.Khan@stjude.org
Lu	Zhaohai	Lilly	lu_zhao_hai@lilly.com

POSTER SESSION

No.	Name	Credentials	Affiliation	Contact	Title
1	Kareem Heslop	PhD	Genentech	heslopk@gene.com	TGFβ-P21-CDK axis emerges as a potential route for endocrine resistance in ER+ Breast Cancer
2	Kayla O'Toole	PhD, MSCI	Huntsman Cancer Institute, University of Utah	Kayla.OTOole@hci.utah.edu 802-760-0019	Characterization of the BRAF interactome identifies BRAFV600E<=>TP53 interaction in melanoma
3	Hannah Neuendorf	PhD	Huntsman Cancer Institute, University of Utah	hannah.neuendorf@hci.utah.edu	Investigating Covalent PI3Ka-RAS Inhibitors in NRAS-mutant Melanoma
4	Lori Friedman	PhD	ORIC Pharmaceuticals, Inc.	lori.friedman@oricpharma.com	ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor with Best-in-class Properties, Demonstrates Combination Synergy with AR Inhibitors in Prostate Cancer Models
5	Bingbing Li	M.D., Ph.D	Oregon Health & Science University	lib@ohsu.edu	To label, detect and target newly synthesized proteins for anticancer activity
6	Semiha Kevser Bali	Postdoctoral Researcher	Lawrence Livermore National Laboratory	bali2@llnl.gov 517-775-0948	Oncogenic KRAS Mutations and Their Influence on GTP Hydrolysis Mechanisms
7	Ashish Toshniwal	Postdoctoral Research Fellow	Department of Biochemistry, University of Utah	ashishgtoshniwal@gmail.com 1-321-444-5752	Targeting Mitochondrial Pyruvate Metabolism to Suppress Cancer Cell Growth
8	Headtlove Essel Dadzie	Ms	Huntsman Cancer Institute, University of Utah	headtlove.esseldadzie@utah.edu 929-289-6949	HNF4α Governs Gastric Identity and KRASG12D Inhibitor response in IMA
9	Brandon Murphy	PhD	Huntsman Cancer Institute, University of Utah	brandon.murphy@hci.utah.edu	Elucidating the mechanisms sustaining DTPCs in LUAD
10	Nadege Gitego	PhD	BBOT (BridgeBio Oncology Therapeutics)	nadege.gitego@bbotx.com 404-824-9659	BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models

11	Mona Foth	PhD	Huntsman Cancer Institute, University of Utah	mona.foth@hci.utah.edu	Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-driven Melanoma
12	Rony A. François	MD, PhD	UCSF	rony.francois@ucsf.edu 415-860-0232	Targeting SHOC2 disrupts MAPK signaling, inhibits proliferation, and potentiates MEK inhibitor response in NRAS- and NF1- mutant melanoma cells
13	Miles Piper		Huntsman Cancer Institute, University of Utah	miles.piper@hci.utah.edu	Targeting KRAS in Pancreatic Cancer: Modeling MAPK Reactivation as a Mechanism of Resistance to Pan-RAS Inhibition
14	Balyn Zaro	PhD	UCSF	balyn.zaro@ucsf.edu	Ninhydrin is a covalent warhead selectively engaging proteinaceous arginine residues



CMTRA

The Cancer Molecular Therapeutics
Research Association

Thanks to our 2025 sponsors:



Bristol Myers Squibb

Lilly



GILEAD

Genentech

A Member of the Roche Group



UNIVERSITY OF UTAH
HUNTSMAN
CANCER INSTITUTE

 **Pfizer**



**Revolution
Medicines**